Vatalanib

{
  "id": "MLC-T-ONC-009190",
  "term": "Vatalanib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A substance that is being studied in the treatment of cancer. It belongs to the families of drugs called protein tyrosine kinase inhibitors and VEGF receptor kinase inhibitors. Also called PTK787/ZK 222584.",
    "An orally bioavailable anilinophthalazine with potential antineoplastic activity. Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis. This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms."
  ],
  "synonyms": [
    "PTK787/ZK 222584",
    "CGP79787D"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/vatalanib/"
}